Related Experiment Video
Updated: May 25, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
[Botulinum toxin treatment in children]
Heli Sätilä1, Vesa Vähäsarja, Pasi Paavilainen
1Kanta-Hämeen keskussairaalan lastenneurologinen yksikkö, TAYS:n lastenneurologinen yksikkö.
Insights
Botulinum toxin type A is a safe and effective treatment for children, primarily for spastic equinus gait in cerebral palsy. While potent, adverse events are rare and typically mild, making it well-tolerated in pediatric patients.
Area of Science:
- Neurology
- Pediatrics
- Pharmacology
Context:
- Botulinum toxin type A (BoNT-A) has been used in pediatric patients for nearly two decades.
- Its primary indication is spastic equinus gait in cerebral palsy.
- Emerging uses include idiopathic toe-walking, pain management, drooling, and torticollis.
Purpose:
- To review the established and emerging indications for botulinum toxin type A in pediatric patients.
- To assess the safety and tolerability profile of botulinum toxin type A in children.
- To highlight the established efficacy for specific pediatric neuromuscular conditions.
Summary:
- Botulinum toxin type A is approved for treating spastic equinus gait in children over two years old.
- Despite being a potent neurotoxin, it demonstrates a favorable safety profile in pediatric populations.
- Adverse events are infrequent and generally mild, such as bruising or temporary muscle weakness, with increased risk of generalized events at higher doses.
Impact:
- Botulinum toxin type A offers a valuable therapeutic option for various pediatric conditions.
- Understanding its safety and efficacy supports expanded clinical application.
- This review provides insights for clinicians managing pediatric patients with neuromuscular disorders.
Abstract:
Botulinum toxin type A treatments in children were started nearly 20 years ago. The first and still most common indication is spastic equinus gait in cerebral palsy, but other indications have emerged, such as idiopathic toe-walking, peri- and post-operative pain, drooling and idiopathic congenital torticollis. The official indication for botulinum toxin treatment is spastic equinus gait in children over 2 years of age. Botulinum toxin is known as the most potent toxin. However, it has proved to be safe and well tolerated among paediatric patients. Adverse events are infrequent, mostly bruising and limited, temporary muscle weakness. With higher doses the risk for generalized adverse events increases.
More Related Videos
12:25Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
10:30A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Pharmaceutical Poisoning: Treatment Strategies
Depolarizing Blockers: Pharmocokinetics
Drug Dosing: Infants and Children